Study type

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Non-interventional study

Non-interventional study design

Cross-sectional
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(N03AX16) pregabalin
pregabalin
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

60000
Study design details

Main study objective

1) Summarize misuse and abuse data for pregabalin and each comparator within each country for each data source

Outcomes

Summarize misuse and abuse data for pregabalin and each comparator within each country for each data source, 2) Summarize patterns of polysubstance use of drugs for pregabalin and each comparator to assess frequency of joint use of drugs within each country, data source, and time period of interest

Data analysis plan

The market authorization holder will estimate rates or prevalence estimates for each of the outcomes (non-medical use, misuse, abuse, intentional exposures) by program for pregabalin and comparators within each country using descriptive statistics.